NewAmsterdam Pharma (NAMS) Liabilities and Shareholders Equity (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $732.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 10.48% year-over-year to $732.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.1 billion (up 20.81% YoY), and the FY2025 full-year result was $769.3 million, down 11.03% from the prior year.
• Liabilities and Shareholders Equity declined to $732.6 million in Q1 2026, from $769.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $864.6 million in Q4 2024 to a low of $512990.1 in Q2 2023.
• A 5-year average of $587.6 million and a median of $637.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 36.0% in 2023 and surged 86975.75% in 2024, its largest moves.
• Tracing NAMS's Liabilities and Shareholders Equity over 5 years: stood at $542.3 million in 2022, then sank by 36.0% to $347.1 million in 2023, then surged by 149.1% to $864.6 million in 2024, then declined by 11.03% to $769.3 million in 2025, then decreased by 4.76% to $732.6 million in 2026.
• Business Quant data shows NAMS's Liabilities and Shareholders Equity at $732.6 million in Q1 2026, $769.3 million in Q4 2025, and $786.4 million in Q3 2025.